TABLE S2.
Responder analyses (full analysis set).
| Treatment group, n (%) | Odds ratio (95% CI) | ||||||
|---|---|---|---|---|---|---|---|
| CTC (n = 184) | Tramadol (n = 183) | Celecoxib (n = 181) | Placebo (n = 89) | CTC versus tramadol | CTC versus celecoxib | CTC versus placebo | |
| Responders 50% a , b | 115 (62.5) | 107 (58.5) | 107 (59.1) | 49 (55.1) | 1.204 (0.777, 1.864) | 1.167 (0.752, 1.811) | 1.377 (0.806, 2.353) |
| Responders 30% a , c | 128 (69.6) | 118 (64.5) | 128 (70.7) | 58 (62.5) | 1.303 (0.820, 2.070) | 0.937 (0.582, 1.507) | 1.230 (0.696, 2.174) |
| Responders NRS <4 a , d | 117 (63.6) | 108 (59.0) | 109 (60.2) | 49 (55.1) | 1.245 (0.800, 1.939) | 1.160 (0.743, 1.811) | 1.440 (0.838, 2.473) |
| Responders 50% and NRS <4 a | 113 (61.4) | 105 (57.4) | 105 (58.0) | 46 (51.7) | 1.202 (0.778, 1.855) | 1.164 (0.752, 1.800) | 1.509 (0.887, 2.569) |
| Responders 30% and NRS <4 a | 117 (63.6) | 108 (59.0) | 109 (60.2) | 49 (55.1) | 1.245 (0.800, 1.939) | 1.160 (0.743, 1.811) | 1.440 (0.838, 2.473) |
Abbreviations: CI, confidence interval; CTC, celecoxib‐tramadol co‐crystal; NRS, numerical rating scale.
a
Logistic regression adjusted for center and baseline pain.
b
A 50% reduction in pain intensity from baseline sustained until the end of the 48‐h observation period.
c
A 30% reduction in pain intensity from baseline sustained until the end of the 48‐h observation period.
d
A pain intensity below 4 on the NRS sustained until the end of the 48‐h observation period.